No Data
No Data
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating, Maintains Target Price $11
Grace Therapeutics Announces Alignment With The FDA Supporting Its Planned NDA Submission For GTx-104
Express News | Grace Therapeutics, Inc: Anticipates Filing Its Nda for Gtx-104 in Q2 of 2025
Grace Therapeutics Announces Alignment With the FDA Supporting the Planned NDA Submission for GTx-104
Express News | Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Grace Therapeutics Reports Q3 Progress and Financial Results